JP3778357B2 - デコイを含む薬学的組成物およびその使用方法 - Google Patents

デコイを含む薬学的組成物およびその使用方法 Download PDF

Info

Publication number
JP3778357B2
JP3778357B2 JP2002565628A JP2002565628A JP3778357B2 JP 3778357 B2 JP3778357 B2 JP 3778357B2 JP 2002565628 A JP2002565628 A JP 2002565628A JP 2002565628 A JP2002565628 A JP 2002565628A JP 3778357 B2 JP3778357 B2 JP 3778357B2
Authority
JP
Japan
Prior art keywords
decoy
ointment
composition
skin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002565628A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2002066070A1 (ja
Inventor
竜一 森下
元邦 青木
俊男 荻原
安史 金田
弘重 中邨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Publication of JPWO2002066070A1 publication Critical patent/JPWO2002066070A1/ja
Application granted granted Critical
Publication of JP3778357B2 publication Critical patent/JP3778357B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2002565628A 2001-02-20 2002-02-06 デコイを含む薬学的組成物およびその使用方法 Expired - Lifetime JP3778357B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20
JP2001044350 2001-02-20
PCT/JP2002/000990 WO2002066070A1 (fr) 2001-02-20 2002-02-06 Compositions pharmaceutiques contenant un leurre et procede d'utilisation associe

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005128753A Division JP4305857B2 (ja) 2001-02-20 2005-04-26 デコイを含む薬学的組成物およびその使用方法

Publications (2)

Publication Number Publication Date
JPWO2002066070A1 JPWO2002066070A1 (ja) 2004-06-17
JP3778357B2 true JP3778357B2 (ja) 2006-05-24

Family

ID=18906362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002565628A Expired - Lifetime JP3778357B2 (ja) 2001-02-20 2002-02-06 デコイを含む薬学的組成物およびその使用方法
JP2009026797A Expired - Lifetime JP4987022B2 (ja) 2001-02-20 2009-02-06 デコイを含む薬学的組成物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009026797A Expired - Lifetime JP4987022B2 (ja) 2001-02-20 2009-02-06 デコイを含む薬学的組成物およびその使用方法

Country Status (11)

Country Link
US (2) US9012417B2 (cg-RX-API-DMAC7.html)
EP (2) EP1362600B1 (cg-RX-API-DMAC7.html)
JP (2) JP3778357B2 (cg-RX-API-DMAC7.html)
AT (1) ATE390938T1 (cg-RX-API-DMAC7.html)
CY (1) CY1108165T1 (cg-RX-API-DMAC7.html)
DE (1) DE60225899T2 (cg-RX-API-DMAC7.html)
DK (1) DK1362600T3 (cg-RX-API-DMAC7.html)
ES (1) ES2307733T3 (cg-RX-API-DMAC7.html)
PT (1) PT1362600E (cg-RX-API-DMAC7.html)
TW (1) TWI308492B (cg-RX-API-DMAC7.html)
WO (1) WO2002066070A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508947A (ja) * 2001-10-04 2005-04-07 アボンテック、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Ｓｔａｔ−１の阻害
JP2008056611A (ja) * 2006-08-31 2008-03-13 Hosokawa Funtai Gijutsu Kenkyusho:Kk 医薬製剤
JP2009102428A (ja) * 2001-02-20 2009-05-14 Anges Mg Inc デコイを含む薬学的組成物およびその使用方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US20070066935A1 (en) * 2003-05-09 2007-03-22 Ryuichi Morishita Needleless syringe having medical agent accomodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
US20070293447A1 (en) * 2003-08-29 2007-12-20 Yasuo Kunugiza Gene Therapy for Skin Disorders Using Needleless Syringes
JP2007512845A (ja) * 2003-12-02 2007-05-24 アネシバ・インコーポレイテッド Ｎｆ−κｂオリゴヌクレオチドデコイ分子
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
WO2006034433A2 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
US8067384B2 (en) 2004-10-22 2011-11-29 Anges Mg, Inc. Chimera (double) decoy
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
EP1892293A4 (en) * 2005-06-06 2008-12-10 Anges Mg Inc TRANSCRIPTION FACTOR DECOY
US20100035793A1 (en) * 2005-07-27 2010-02-11 Cheh Peng Lim Modulators
US20100167390A1 (en) * 2005-12-22 2010-07-01 Toshohiro Nakajima Novel Oligonucleotide and NF-kB Decoy Comprising the Same
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
WO2008099906A1 (ja) 2007-02-16 2008-08-21 Anges Mg, Inc. 歯周病、及び外科手術による歯槽骨欠損の治療剤
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
HRP20150759T1 (hr) 2007-05-11 2015-08-14 Adynxx, Inc. Ekspresija gena i bolovi
WO2009119836A1 (ja) * 2008-03-28 2009-10-01 アンジェスＭｇ株式会社 転写因子デコイを有効成分とする外用剤組成物
PT2846839T (pt) 2012-05-10 2019-05-29 Adynxx Inc Formulações para a administração de ingredientes ativos
BR112017002629A2 (pt) 2014-08-15 2018-02-20 Adynxx, Inc. decoys de oligonucleotídeo para o tratamento de dor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6150090A (en) 1986-01-09 2000-11-21 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
JPH05331066A (ja) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk 尋常性ざ瘡治療用組成物
PT732929E (pt) * 1993-10-29 2008-08-26 Brigham & Womens Hospital Utilização terapêutica de ''engodos'' de elementos cis in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
CA2203566C (en) * 1994-10-24 2001-10-23 Yuko Hosokawa Percutaneously administration preparation
ES2285712T3 (es) 1995-05-12 2007-11-16 Anges Mg, Inc. Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
JPH11507245A (ja) * 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
CA2294988C (en) * 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (ja) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd アトピー性皮膚炎治療剤
WO2001057204A1 (en) * 2000-02-02 2001-08-09 Yasufumi Kaneda Virus envelope vector for gene transfer
DE10049549A1 (de) * 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
TWI308492B (cg-RX-API-DMAC7.html) 2001-02-20 2009-04-11 Anges Mg Inc
WO2003063911A1 (en) * 2002-02-01 2003-08-07 Anges Mg, Inc. Decoy-containing pharmaceutical compositions and method of using the same
JP4971609B2 (ja) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 核酸皮膚外用製剤
JP2006111591A (ja) 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009102428A (ja) * 2001-02-20 2009-05-14 Anges Mg Inc デコイを含む薬学的組成物およびその使用方法
US9012417B2 (en) 2001-02-20 2015-04-21 Anges Mg, Inc. Topical administration of NF-kappaB decoy to treat atopic dermatitis
JP2005508947A (ja) * 2001-10-04 2005-04-07 アボンテック、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング Ｓｔａｔ−１の阻害
JP2008056611A (ja) * 2006-08-31 2008-03-13 Hosokawa Funtai Gijutsu Kenkyusho:Kk 医薬製剤

Also Published As

Publication number Publication date
PT1362600E (pt) 2008-07-09
EP1690544B1 (en) 2017-09-13
DK1362600T3 (da) 2008-07-28
TWI308492B (cg-RX-API-DMAC7.html) 2009-04-11
JP2009102428A (ja) 2009-05-14
JPWO2002066070A1 (ja) 2004-06-17
US9012417B2 (en) 2015-04-21
EP1690544A3 (en) 2012-03-07
EP1362600A4 (en) 2005-09-21
EP1690544A2 (en) 2006-08-16
DE60225899D1 (de) 2008-05-15
ES2307733T3 (es) 2008-12-01
WO2002066070A1 (fr) 2002-08-29
US20090105183A1 (en) 2009-04-23
EP1362600A1 (en) 2003-11-19
ATE390938T1 (de) 2008-04-15
DE60225899T2 (de) 2009-04-09
EP1362600B1 (en) 2008-04-02
US20040162251A1 (en) 2004-08-19
CY1108165T1 (el) 2014-02-12
JP4987022B2 (ja) 2012-07-25

Similar Documents

Publication Publication Date Title
JP4987022B2 (ja) デコイを含む薬学的組成物およびその使用方法
JP3474879B2 (ja) ＮＦ−κＢに起因する疾患の治療および予防剤
US8067388B2 (en) Decoy-containing pharmaceutical compositions and method of using the same
JPWO1996035430A1 (ja) ＮＦ−κＢに起因する疾患の治療および予防剤
AU2002255285A1 (en) Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
JPWO2003099339A1 (ja) 炎症性疾患を処置および予防するためのデコイ組成物
US6890909B1 (en) Brain-protective agent
JPWO1999001155A1 (ja) 脳保護剤
JP4305857B2 (ja) デコイを含む薬学的組成物およびその使用方法
JP4346233B2 (ja) デコイを含む薬学的組成物およびその使用方法
JP2002193813A5 (cg-RX-API-DMAC7.html)
JP4033502B2 (ja) リボザイム、リポソーム製剤及びその用途
JP5057587B2 (ja) デコイを含む薬学的組成物およびその使用方法
JP2003128559A (ja) ＮＦ−κＢに起因する疾患の治療および予防剤
JPWO2005074988A1 (ja) 神経細胞分化誘導剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050426

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20050426

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20050520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050802

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20060222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20060222

R150 Certificate of patent or registration of utility model

Ref document number: 3778357

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090310

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100310

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100310

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110310

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110310

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160310

Year of fee payment: 10

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term